• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center


    CanCORS: Understanding the reasons for cancer care disparities

    Jane Weeks, MD, MSc, ScM (DFCI), co-leader of the DF/HCC Outcomes Research Program, was convinced she knew why elderly patients with colorectal cancer were much less likely to receive adjuvant chemotherapy than were their younger counterparts

    First trial of multi-targeted inhibitor in patients with metastatic colorectal cancer

    Although the median survival rate for patients with metastatic colorectal cancer has doubled over the past decade, it remains only about 24 months

    DF/HCC Skin SPORE renewed

    The DF/HCC Skin SPORE, led by Thomas Kupper, MD (BWH), has been highly successful in creating cohesion in the Cutaneous Oncology and Melanoma program, sparking new collaborative grants, fostering innovative ideas in cancer research, and advancing the careers of junior investigators

    DF/HCC members awarded grants amid tight funding environment

    The NIH continues to recognize DF/HCC as a leader in cancer research by awarding funding to a number of our research initiatives

    Raynard S. Kington named NIH Acting Director
    Thinking therapeutically: Scientists in search of smarter tests and treatments for prostate cancer

    Even though prostate cancer is the second leading cause of cancer death in men in the United States, some patients may wonder whether treatment is worse than the disease

    Beyond survival: Bettering menís quality of life following prostate cancer treatment

    Few clinicians understand the consequences of prostate cancer treatment better than urological surgeon-scientist Martin Sanda, MD, director of the multidisciplinary prostate cancer clinic at BIDMC

Displaying results 120 to 126 out of 206